FindTrial
Sign In

Collection of ophthalmic data to predict the effectiveness of Anti-VEGF treatment in diabetic patients by assessing the retinal thickness using artificial intelligence tools.

Quantitative Analyses and Prediction of anti-VEGF treatment effectiveness in Diabetic Macular Edema (DME) and neovascular Age related Macular Degeneration (nAMD) with relation to central subfield thickness (CST) and sub retinal fluid volume outcomes, respectively, using machine learning (ML) methods

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/05/033844
Enrollment
1500
Registered
2021-05-28
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E113- Type 2 diabetes mellitus with ophthalmic complications

Interventions

None listed

Sponsors

Carl Zeiss India Bangalore Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Males or females 18 years of age or older 2. Patients who underwent OCT examination on CIRRUS HD OCT 5000 and/or Spectralis OCT 3. Type I or Type II diabetes with the case of DME in both eyes 4. Patients who underwent Anti-VEGF treatment

Exclusion criteria

Exclusion criteria: 1. Subjects less than 18 years of age 2. Non-Diabetic subjects 3. Subjects with any comorbidities 4. Case of macular edema due to causes other than DME 5. Patients without follow up data 6. Patients with no pre-OCT data

Design outcomes

Primary

MeasureTime frame
To classify non responders from responders in response to Anti ââ?¬â?? VEGF treatment in DME management. Timepoint: The data collection and prediction algorithm development are estimated to be completed in 1 year from the time of ethics committee approval and study initiation at the site.—

Secondary

MeasureTime frame
To develop and validate the AI based algorithm for prediction towards Anti ââ?¬â?? VEGF response in patients with DME yielding central sub-field thickness (CST).Timepoint: The data collection and prediction algorithm development are estimated to be completed in 1 year from the time of ethics committee approval and study initiation at the site.—

Countries

India

Contacts

Public ContactDr T C Ganesh Babu

Carl Zeiss India (Bangalore) Pvt Ltd

ganesh.babu@zeiss.com9880225622

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026